

01 July 2021

Preventx expands into Europe

[Synova](#) portfolio company, [Preventx](#), the UK's leading provider of online-led sexual health diagnostic services is pleased to announce its expansion into Europe via two complimentary acquisitions.

Preventx has acquired [Soapoli Online \(SPO\)](#), the largest provider of self-sample sexual health testing services in the Netherlands and [Open House](#), a private provider of sexual health testing based in Madrid.

The two businesses are leaders in their respective domestic markets where there is opportunity for significant growth and together will form the cornerstone of Preventx's expansion into adjacent European markets. The combination of acquired local market knowledge and Preventx's leading technology platform and experience of providing [Europe's largest remote testing service of its kind in London](#) will be highly synergistic.

This acquisition follows on from the recent expansion of Preventx's specialised laboratory testing facility in Sheffield as the uptake of online-led sexual health services continues to increase.

CEO of Preventx, Ruth Poole, commented: *"The UK is leading the world in normalising online-led sexual health testing and treatment. These important acquisitions will position Preventx to become the European leader in sexual health, enabling millions more people to access reliable and convenient services."*

"The Netherlands has some of the highest usage of digital health in the world. In SPO we inherit a strong business that will provide a springboard into the sexual health market there and Open House's strong reputation will enable us to make remote testing services more widely available in Spain where provision is currently limited."

Tim Ashlin, Partner at Synova and Director of Preventx, noted: *"These acquisitions represent a significant milestone in Preventx's journey and Synova continues to support the team's ambitious strategy to expand both in the UK and overseas through a combination of organic investment and M&A."*

ENDS

1/2

NOTES:

1. **Synova** is recognised across the industry as one of Europe's most innovative growth investors, investing in companies typically valued between £30m and £150m. We invest across a handful of core sectors, including **Technology**, **Financial Services**, **Business Services**, and **Health & Education**, where we have deep investment and operational expertise
2. Synova has generated industry-leading returns, which has been reflected in being awarded '*Private Equity House of the Year*' four times in the past seven years. Synova was recently listed as one of the '*Most Consistent Top Performing Buyout Fund Managers*' globally by *Preqin*. Synova is the only private equity firm in the UK, and one of only two in Europe, with a number one *Preqin* ranking with all of its applicable funds ranked in the top quartile, placing Synova as one of the Top 9 best performers globally
3. Synova has completed a number of new investments and successful exits across the **Health** sector with the sale of **4Ways** to ECI Partners (6.0x invested capital) and **Kinapse** to HgCapital (16.1x invested capital); and investments in **Charnwood Molecular** (drug discovery services), **Preventx** (online-led sexual health testing and diagnostics), **Clyde Munro** (Scottish dental consolidation platform) and **Oakland Care** (premium residential elderly care)

CONTACT:

SYNOVA Mike Mullally
Tel: +44 (0)79 1785 4343

Tim Ashlin
Tel: +44 (0)20 3475 7668